Bayer Animal Health receives EU approval for two new drugs

Bayer Animal Health has been granted approval to launch a pair of new veterinary medicine products in the EU.

The European Commission has ratified the fluoroquinolone antibiotic Veraflox and the roundworm and coccidian treatment Procox for sale, with initial launches to take place in Germany and Austria shortly.

Veraflox represents the first next-generation veterinary fluoroquinolone antibiotic for treating bacterial infections among cats and dogs and has been approved for use among animals with conditions such as wound infections, pyoderma and urinary tract infections.

Meanwhile, Procox becomes the first and only parasiticide of its kind licensed as a combination therapy for roundworm and coccidia in canines, with Bayer Animal Health stating that it can be conveniently used among puppies.

Luc Lowinski, managing director of Bayer Animal Health, said: "We have a strong and ongoing commitment to researching and developing innovative ways to address parasitic and bacterial infections in companion animals."

In November 2010, the company expanded its portfolio with the acquisition of chewable application technology from Piedmont Pharmaceuticals for use in its future products.